Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-12-16 00:00:00 ET · period of report 2025-12-12 · accession 0002001011-25-000125 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-16 | 2025-12-12 | LGND | Espinoza Octavio | CFO | S - Sale | $188.31 | -1,804 | 26.2K | -6% | -$339.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | S | D | 1,804 | $188.31 | 26,186 | D | — | — |